{"pmid":32483236,"title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.","text":["Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.","Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.","Nat Commun","Poh, Chek Meng","Carissimo, Guillaume","Wang, Bei","Amrun, Siti Naqiah","Lee, Cheryl Yi-Pin","Chee, Rhonda Sin-Ling","Fong, Siew-Wai","Yeo, Nicholas Kim-Wah","Lee, Wen-Hsin","Torres-Ruesta, Anthony","Leo, Yee-Sin","Chen, Mark I-Cheng","Tan, Seow-Yen","Chai, Louis Yi Ann","Kalimuddin, Shirin","Kheng, Shirley Seah Gek","Thien, Siew-Yee","Young, Barnaby Edward","Lye, David C","Hanson, Brendon John","Wang, Cheng-I","Renia, Laurent","Ng, Lisa F P","32483236"],"abstract":["Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus."],"journal":"Nat Commun","authors":["Poh, Chek Meng","Carissimo, Guillaume","Wang, Bei","Amrun, Siti Naqiah","Lee, Cheryl Yi-Pin","Chee, Rhonda Sin-Ling","Fong, Siew-Wai","Yeo, Nicholas Kim-Wah","Lee, Wen-Hsin","Torres-Ruesta, Anthony","Leo, Yee-Sin","Chen, Mark I-Cheng","Tan, Seow-Yen","Chai, Louis Yi Ann","Kalimuddin, Shirin","Kheng, Shirley Seah Gek","Thien, Siew-Yee","Young, Barnaby Edward","Lye, David C","Hanson, Brendon John","Wang, Cheng-I","Renia, Laurent","Ng, Lisa F P"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483236","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1038/s41467-020-16638-2","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668704334372667393,"score":9.490897,"similar":[{"pmid":32473352,"title":"Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.","text":["Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.","The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify B- and T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs.","Infect Genet Evol","Vashi, Yoya","Jagrit, Vipin","Kumar, Sachin","32473352"],"abstract":["The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify B- and T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs."],"journal":"Infect Genet Evol","authors":["Vashi, Yoya","Jagrit, Vipin","Kumar, Sachin"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473352","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.meegid.2020.104382","keywords":["diagnostics","epitopes","sars-cov-2","spike protein"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193388548096,"score":458.79245},{"pmid":32419646,"title":"Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study.","text":["Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study.","The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silica tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.","J Biomol Struct Dyn","K, Abraham Peele","T, Srihansa","S, Krupanidhi","A, Vijaya Sai","Tc, Venkateswarulu","32419646"],"abstract":["The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silica tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19."],"journal":"J Biomol Struct Dyn","authors":["K, Abraham Peele","T, Srihansa","S, Krupanidhi","A, Vijaya Sai","Tc, Venkateswarulu"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419646","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/07391102.2020.1770127","keywords":["covid-19","iedb","spike glycoprotein","vaccine design","vaxigen","immuno-informatics"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284572487682,"score":351.83798},{"pmid":32155444,"pmcid":"PMC7102599","title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","text":["Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.","Cell","Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David","32155444"],"abstract":["The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination."],"journal":"Cell","authors":["Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32155444","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.cell.2020.02.058","keywords":["sars-cov","sars-cov-2","antibodies","coronavirus","cryo-em","neutralizing antibodies","spike glycoprotein","viral receptor"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490664910848,"score":330.11472},{"pmid":32413276,"title":"Identification of Human Single-Domain Antibodies against SARS-CoV-2.","text":["Identification of Human Single-Domain Antibodies against SARS-CoV-2.","The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic target. We describe the development of a phage-displayed single-domain antibody library by grafting naive complementarity-determining regions (CDRs) into framework regions of a human germline immunoglobulin heavy chain variable region (IGHV) allele. Panning this library against SARS-CoV-2 RBD and S1 subunit identified fully human single-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. Some of these antibodies neutralize SARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interface. Collectively, this work presents a versatile platform for rapid antibody isolation and identifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverse immogneic profile of the spike protein.","Cell Host Microbe","Wu, Yanling","Li, Cheng","Xia, Shuai","Tian, Xiaolong","Kong, Yu","Wang, Zhi","Gu, Chenjian","Zhang, Rong","Tu, Chao","Xie, Youhua","Yang, Zhenlin","Lu, Lu","Jiang, Shibo","Ying, Tianlei","32413276"],"abstract":["The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1 subunit involved in receptor engagement, is a potential therapeutic target. We describe the development of a phage-displayed single-domain antibody library by grafting naive complementarity-determining regions (CDRs) into framework regions of a human germline immunoglobulin heavy chain variable region (IGHV) allele. Panning this library against SARS-CoV-2 RBD and S1 subunit identified fully human single-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. Some of these antibodies neutralize SARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interface. Collectively, this work presents a versatile platform for rapid antibody isolation and identifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverse immogneic profile of the spike protein."],"journal":"Cell Host Microbe","authors":["Wu, Yanling","Li, Cheng","Xia, Shuai","Tian, Xiaolong","Kong, Yu","Wang, Zhi","Gu, Chenjian","Zhang, Rong","Tu, Chao","Xie, Youhua","Yang, Zhenlin","Lu, Lu","Jiang, Shibo","Ying, Tianlei"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413276","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.04.023","keywords":["cr3022","rbd","sars-cov-2","nanobody","single-domain antibody","trimeric interface"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319092551681,"score":325.8985},{"pmid":32396773,"title":"Truncated human Angiotensin Converting Enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.","text":["Truncated human Angiotensin Converting Enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.","The current pandemic of Covid-19 caused by SARS-CoV-2 is continued to spread globally and no potential drug or vaccine against it is available. Spike (S) glycoprotein is the structural protein of SARS-CoV-2 located on the envelope surface, involve in interaction with angiotensin converting enzyme 2 (ACE2), a cell surface receptor, followed by entry into the host cell. Thereby, blocking the S glycoprotein through potential inhibitor may interfere its interaction with ACE2 and impede its entry into the host cell. Here, we present a truncated version of human ACE2 (tACE2), comprising the N terminus region of the intact ACE2 from amino acid position 21-119, involved in binding with receptor binding domain (RBD) of SARS-CoV-2. We analyzed the in-silico potential of tACE2 to compete with intact ACE2 for binding with RBD. The protein-protein docking and molecular dynamic simulation showed that tACE2 has higher binding affinity for RBD and form more stabilized complex with RBD than the intact ACE2. Furthermore, prediction of tACE2 soluble expression in E. coli makes it a suitable candidate to be targeted for Covid-19 therapeutics. This is the first MD simulation based findings to provide a high affinity protein inhibitor for SARS-CoV-2 S glycoprotein, an important target for drug designing against this unprecedented challenge.","J Biomol Struct Dyn","Basit, Abdul","Ali, Tanveer","Rehman, Shafiq Ur","32396773"],"abstract":["The current pandemic of Covid-19 caused by SARS-CoV-2 is continued to spread globally and no potential drug or vaccine against it is available. Spike (S) glycoprotein is the structural protein of SARS-CoV-2 located on the envelope surface, involve in interaction with angiotensin converting enzyme 2 (ACE2), a cell surface receptor, followed by entry into the host cell. Thereby, blocking the S glycoprotein through potential inhibitor may interfere its interaction with ACE2 and impede its entry into the host cell. Here, we present a truncated version of human ACE2 (tACE2), comprising the N terminus region of the intact ACE2 from amino acid position 21-119, involved in binding with receptor binding domain (RBD) of SARS-CoV-2. We analyzed the in-silico potential of tACE2 to compete with intact ACE2 for binding with RBD. The protein-protein docking and molecular dynamic simulation showed that tACE2 has higher binding affinity for RBD and form more stabilized complex with RBD than the intact ACE2. Furthermore, prediction of tACE2 soluble expression in E. coli makes it a suitable candidate to be targeted for Covid-19 therapeutics. This is the first MD simulation based findings to provide a high affinity protein inhibitor for SARS-CoV-2 S glycoprotein, an important target for drug designing against this unprecedented challenge."],"journal":"J Biomol Struct Dyn","authors":["Basit, Abdul","Ali, Tanveer","Rehman, Shafiq Ur"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396773","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/07391102.2020.1768150","keywords":["ace2","inhibitor","md simulation","protein-protein docking","sars-cov-2","spike glycoprotein"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827915554816,"score":319.24722}]}